All In Biotech

Drug Trial Radar · NCT05999357

JDQ443 for KRAS G12C NSCLC Brain Metastases

A Phase II Study evaluaTing intRacranial effIcacy of JDQ443 in patiEnts With KRAS G12C+ NSCLC and bRain Metastases

Last checked: Nov 19, 2026Latest source record: May 29, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Withdrawn

Status

Withdrawn

Enrollment

0

Actual

Start

Apr 15, 2024

Primary completion

Aug 2027

Study completion Aug 2028

Sponsor

Lead sponsor
Maastricht University Medical CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Novartis
First posted
Aug 21, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this phase II clinical trial is to evaluate the intracranial efficacy of JDQ443, a KRAS G12C inhibitor in patients with KRAS G12C+ NSCLC and brain metastases (cohort A: asymptomatic, untreated brain metastases, cohort B: asymptomatic, treated brain metastases). The main question it aims to answer is to evaluate the intracranial efficacy, according to RANO-BM criteria, in patients with asymptomatic and untreated brain metastases. Participants will receive JDQ443 200 mg BID until unacceptable toxicity or disease progression.

Conditions

  • Non Small Cell Lung Cancer Metastatic
  • Brain Metastases, Adult
  • KRAS G12C

Interventions

  • JDQ443Drug

    JDQ443 tablets, orally administered

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. brain metastases overall response rate (ORR)Time frame: up to 24 months

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.